872422-15-6

Basic information

• Product Name: 1-(4-BroMo-2-fluorophenyl)cyclopropanecarboxylic acid
• Synonyms: 1-(4-BroMo-2-fluorophenyl)cyclopropanecarboxylic acid;1-(4-BroMo-2-fluorophenyl)cyclopropane-1-carboxylic acid
• CAS NO: 872422-15-6
• Molecular Formula: C₁₀H₈BrFO₂
• Molecular Weight: 259.0717232
• Mol File: 872422-15-6.mol

Chemical Properties

• Boiling Point: 350.9±42.0 °C(Predicted)
• Appearance: /
• Density: 1.744±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 3.81±0.20(Predicted)
• CAS DataBase Reference: 1-(4-BroMo-2-fluorophenyl)cyclopropanecarboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-BroMo-2-fluorophenyl)cyclopropanecarboxylic acid(872422-15-6)
• EPA Substance Registry System: 1-(4-BroMo-2-fluorophenyl)cyclopropanecarboxylic acid(872422-15-6)

Safety Data

• Hazardous Substances Data: 872422-15-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-(4-Bromo-2-fluorophenyl)cyclopropanecarboxylic acid is used as an intermediate in the synthesis of various pharmaceuticals for its potential pharmacological activities. Its unique structure allows for the development of new drugs with specific therapeutic effects.
Used in Agrochemical Industry:
In the agrochemical industry, 1-(4-Bromo-2-fluorophenyl)cyclopropanecarboxylic acid is utilized as a key intermediate in the production of agrochemicals. Its chemical properties contribute to the creation of effective compounds for agricultural applications, such as pesticides and herbicides.
Used in Chemical Research and Development:
1-(4-Bromo-2-fluorophenyl)cyclopropanecarboxylic acid serves as a valuable building block in chemical research and development. Its unique structure and properties facilitate the exploration of new chemical compounds with potential applications across various industries, including medicine and agriculture.

Upstream product

• 114897-91-5 (4-bromo-2-fluorophenyl)acetonitrile 
• 107-04-0 1-Bromo-2-chloroethane 
• 76283-09-5 4-bromo-2-fluorobenzyl bromide 
• 749928-88-9 1-(4-bromo-2-fluorophenyl)cyclopropane-1-carbonitrile 

Downstream Products

• 827628-31-9 [1-(4-bromo-2-fluorophenyl)cyclopropyl]carbamic acid tert-butyl ester 
• 1403395-94-7 [(8R)-3-{1-[2-fluoro-4-(6-methylpyridazin-3-yl)phenyl]cyclopropyl}-8-methyl-5,6,8,9-tetrahydro[1,2,4]triazolo[4,3-d][1,4]thiazepin-8-yl]methanol 
• 1403397-00-1 (8R)-8-({[tert-butyl(dimethyl)silyl]oxy}methyl)-3-{1-[2-fluoro-4-(6-methylpyridazin-3-yl)phenyl]cyclopropyl}-8-methyl-5,6,8,9-tetrahydro[1,2,4]triazolo[4,3-d][1,4]thiazepine 
• 1403396-99-5 (8R)-8-({[tert-butyl(dimethyl)silyl]oxy}methyl)-3-{1-[2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]cyclopropyl}-8-methyl-5,6,8,9-tetrahydro[1,2,4]triazolo[4,3-d][1,4]thiazepine 
• 1403395-86-7 {(8R)-3-{1-[2-fluoro-4-(1-methyl-1H-pyrazol-4-yl)phenyl]cyclopropyl}-8-methyl-5,6,8,9-tetrahydro[1,2,4]triazolo[4,3-d][1,4]thiazepin-8-yl}methanol 
• 1403396-90-6 (8R)-8-({[tert-butyl(dimethyl)silyl]oxy}methyl)-3-{1-[2-fluoro-4-(1-methyl-1H-pyrazol-4-yl)phenyl]cyclopropyl}-8-methyl-5,6,8,9-tetrahydro[1,2,4]triazolo[4,3-d][1,4]thiazepine 
• 1403396-89-3 (8R)-3-[1-(4-bromo-2-fluorophenyl)cyclopropyl]-8-({[tert-butyl(dimethyl)silyl]oxy}methyl)-8-methyl-5,6,8,9-tetrahydro[1,2,4]triazolo[4,3-d][1,4]thiazepine 
• 1403395-85-6 (3-{1-[2-fluoro-4-(1-methyl-1H-pyrazol-4-yl)phenyl]cyclopropyl}-8-methyl-5,6,8,9-tetrahydro[1,2,4]triazolo[4,3-d][1,4]thiazepin-8-yl)methanol 
• 1403396-88-2 8-({[tert-butyl(dimethyl)silyl]oxy}methyl)-3-{1-[2-fluoro-4-(1-methyl-1H-pyrazol-4-yl)phenyl]cyclopropyl}-8-methyl-5,6,8,9-tetrahydro[1,2,4]triazolo[4,3-d][1,4]thiazepine 
• 1403395-20-9 {3-[1-(2-fluoro-4-pyridin-3-ylphenyl)cyclopropyl]-8-methyl-5,6,8,9-tetrahydro[1,2,4]triazolo[4,3-d][1,4]thiazepin-8-yl}methanol 
• 1403396-18-8 8-({[tert-butyl(dimethyl)silyl]oxy}methyl)-3-[1-(2-fluoro-4-pyridin-3-ylphenyl)cyclopropyl]-8-methyl-5,6,8,9-tetrahydro[1,2,4]triazolo[4,3-d][1,4]thiazepine 
• 1403395-19-6 {3-[1-(3-fluorobiphenyl-4-yl)cyclopropyl]-8-methyl-5,6,8,9-tetrahydro[1,2,4]triazolo[4,3-d][1,4]thiazepin-8-yl}methanol 
• 1403396-16-6 3-[1-(4-bromo-2-fluorophenyl)cyclopropyl]-8-({[tert-butyl(dimethyl)silyl]oxy}methyl)-8-methyl-5,6,8,9-tetrahydro[1,2,4]triazolo[4,3-d][1,4]thiazepine 
• 1403396-15-5 1-(4-bromo-2-fluorophenyl)cyclopropanecarbohydrazide 

Relevant articles and documents

TETRAHYDROTHIAZEPINE DERIVATIVE

The present invention relates to a compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof having an excellent effect of inhibiting 11β-hydroxysteroid dehydrogenase type 1: General formula (I) wherein R1 represents a phenyl group that may be substituted with 1 to 5 group(s) independently selected from substituent group A or a heterocyclic group that may be substituted with 1 to 4 group(s) independently selected from substituent group A; R2 independently represents a halogen atom or a C1-C6 alkyl group; n represents an integer of 0 to 2; and substituent group A represents the group consisting of halogen atoms, C1-C6 alkyl groups, and so forth.

N-ARYLTRIAZOLE COMPOUNDS AS LPAR ANTAGONISTS

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of inflammatory diseases and disorders such as, for example, pulmonary fibrosis

AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS

The present invention relates to inhibitors of 11-β hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor (MR), and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-β hydroxyl steroid dehydrogenase type 1 and/or diseases associated with aldosterone excess.

Amido compounds and their use as pharmaceuticals

The present invention relates to inhibitors of 11-β hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor MR, and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-β hydroxyl steroid dehydrogenase type 1 and/or diseases associated with aldosterone excess.